Landscape of Cell Banking

Heather C. Hatcher, Anthony Atala, Julie G. Allickson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

As the aging population grows in the United States and globally, regenerative medicine has become an important healthcare sustainability goal, as it has the potential to save billions of dollars in healthcare costs. One important aspect of regenerative medicine is cellular therapy, where the cellular component used in the construction of organs and tissue is extremely vital. Banking stem cells has generally been seen in the bone marrow and cord blood transplant fields for hematopoietic diseases; however, within the last decade regenerative medicine has expanded the use of banked stem cells to neurodegenerative, cardiac, and musculoskeletal diseases. The biobanking field for clinical use includes a public-unrelated/universal-donor model as well as an autologous-source model consisting of privately storing one's own cells. Banking cells for public use or to establish cell lines that could be used for multiple patients may be associated with financial savings, as the execution of federal regulations on one donor cell line would facilitate sourcing individual donors for each patient. With private banking or banking one's own cells, the threat of immune rejection is diminished; however, the time and cost required is a challenge compared to using cell lines or a universal donor. Taking into account the regulatory considerations, time constraints of patient treatment, and financial considerations, both public and private cell banking will play significant roles in the future of translational regenerative medicine.

Original languageEnglish (US)
Title of host publicationTranslational Regenerative Medicine
PublisherElsevier Inc.
Pages13-19
Number of pages7
ISBN (Print)9780124104570, 9780124103962
DOIs
StatePublished - Dec 2 2014
Externally publishedYes

Fingerprint

Regenerative Medicine
Tissue Donors
Cell Line
Stem Cells
Musculoskeletal Diseases
Unrelated Donors
Translational Medical Research
Fetal Blood
Neurodegenerative Diseases
Health Care Costs
Heart Diseases
Bone Marrow
Delivery of Health Care
Transplants
Costs and Cost Analysis
Therapeutics
Population

Keywords

  • Clinical application
  • Public and private cord blood banks
  • Regenerative medicine
  • Translational medicine
  • Umbilical cord blood

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hatcher, H. C., Atala, A., & Allickson, J. G. (2014). Landscape of Cell Banking. In Translational Regenerative Medicine (pp. 13-19). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-410396-2.00002-5

Landscape of Cell Banking. / Hatcher, Heather C.; Atala, Anthony; Allickson, Julie G.

Translational Regenerative Medicine. Elsevier Inc., 2014. p. 13-19.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hatcher, HC, Atala, A & Allickson, JG 2014, Landscape of Cell Banking. in Translational Regenerative Medicine. Elsevier Inc., pp. 13-19. https://doi.org/10.1016/B978-0-12-410396-2.00002-5
Hatcher HC, Atala A, Allickson JG. Landscape of Cell Banking. In Translational Regenerative Medicine. Elsevier Inc. 2014. p. 13-19 https://doi.org/10.1016/B978-0-12-410396-2.00002-5
Hatcher, Heather C. ; Atala, Anthony ; Allickson, Julie G. / Landscape of Cell Banking. Translational Regenerative Medicine. Elsevier Inc., 2014. pp. 13-19
@inbook{a4bedd1b92c94133accbeb1d5fd79dee,
title = "Landscape of Cell Banking",
abstract = "As the aging population grows in the United States and globally, regenerative medicine has become an important healthcare sustainability goal, as it has the potential to save billions of dollars in healthcare costs. One important aspect of regenerative medicine is cellular therapy, where the cellular component used in the construction of organs and tissue is extremely vital. Banking stem cells has generally been seen in the bone marrow and cord blood transplant fields for hematopoietic diseases; however, within the last decade regenerative medicine has expanded the use of banked stem cells to neurodegenerative, cardiac, and musculoskeletal diseases. The biobanking field for clinical use includes a public-unrelated/universal-donor model as well as an autologous-source model consisting of privately storing one's own cells. Banking cells for public use or to establish cell lines that could be used for multiple patients may be associated with financial savings, as the execution of federal regulations on one donor cell line would facilitate sourcing individual donors for each patient. With private banking or banking one's own cells, the threat of immune rejection is diminished; however, the time and cost required is a challenge compared to using cell lines or a universal donor. Taking into account the regulatory considerations, time constraints of patient treatment, and financial considerations, both public and private cell banking will play significant roles in the future of translational regenerative medicine.",
keywords = "Clinical application, Public and private cord blood banks, Regenerative medicine, Translational medicine, Umbilical cord blood",
author = "Hatcher, {Heather C.} and Anthony Atala and Allickson, {Julie G.}",
year = "2014",
month = "12",
day = "2",
doi = "10.1016/B978-0-12-410396-2.00002-5",
language = "English (US)",
isbn = "9780124104570",
pages = "13--19",
booktitle = "Translational Regenerative Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Landscape of Cell Banking

AU - Hatcher, Heather C.

AU - Atala, Anthony

AU - Allickson, Julie G.

PY - 2014/12/2

Y1 - 2014/12/2

N2 - As the aging population grows in the United States and globally, regenerative medicine has become an important healthcare sustainability goal, as it has the potential to save billions of dollars in healthcare costs. One important aspect of regenerative medicine is cellular therapy, where the cellular component used in the construction of organs and tissue is extremely vital. Banking stem cells has generally been seen in the bone marrow and cord blood transplant fields for hematopoietic diseases; however, within the last decade regenerative medicine has expanded the use of banked stem cells to neurodegenerative, cardiac, and musculoskeletal diseases. The biobanking field for clinical use includes a public-unrelated/universal-donor model as well as an autologous-source model consisting of privately storing one's own cells. Banking cells for public use or to establish cell lines that could be used for multiple patients may be associated with financial savings, as the execution of federal regulations on one donor cell line would facilitate sourcing individual donors for each patient. With private banking or banking one's own cells, the threat of immune rejection is diminished; however, the time and cost required is a challenge compared to using cell lines or a universal donor. Taking into account the regulatory considerations, time constraints of patient treatment, and financial considerations, both public and private cell banking will play significant roles in the future of translational regenerative medicine.

AB - As the aging population grows in the United States and globally, regenerative medicine has become an important healthcare sustainability goal, as it has the potential to save billions of dollars in healthcare costs. One important aspect of regenerative medicine is cellular therapy, where the cellular component used in the construction of organs and tissue is extremely vital. Banking stem cells has generally been seen in the bone marrow and cord blood transplant fields for hematopoietic diseases; however, within the last decade regenerative medicine has expanded the use of banked stem cells to neurodegenerative, cardiac, and musculoskeletal diseases. The biobanking field for clinical use includes a public-unrelated/universal-donor model as well as an autologous-source model consisting of privately storing one's own cells. Banking cells for public use or to establish cell lines that could be used for multiple patients may be associated with financial savings, as the execution of federal regulations on one donor cell line would facilitate sourcing individual donors for each patient. With private banking or banking one's own cells, the threat of immune rejection is diminished; however, the time and cost required is a challenge compared to using cell lines or a universal donor. Taking into account the regulatory considerations, time constraints of patient treatment, and financial considerations, both public and private cell banking will play significant roles in the future of translational regenerative medicine.

KW - Clinical application

KW - Public and private cord blood banks

KW - Regenerative medicine

KW - Translational medicine

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=84942741317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942741317&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-410396-2.00002-5

DO - 10.1016/B978-0-12-410396-2.00002-5

M3 - Chapter

SN - 9780124104570

SN - 9780124103962

SP - 13

EP - 19

BT - Translational Regenerative Medicine

PB - Elsevier Inc.

ER -